Table 3.
Features predicting long‐term HRQoL among respondents (n = 230)
| 15D score | EORTC QLQ‐C30 Global health status | ||||
|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 1 | Model 2 | ||
| Adjusted R square | 0.060 | 0.119 | 0.041 | 0.088 | |
| Mean ± SD or N (%) | Coefficient (Sig.) | ||||
|---|---|---|---|---|---|
| Constant | 0.798 | 0.854 | 52.5 | 54.2 | |
| Preoperative features | |||||
| Time since operation (months) | 70.0 ± 29.4 | −0.001 (0.041) | |||
| Age at operation | 63.0 ± 8.7 | ||||
| Male | 122 (53.0) | ||||
| SPY | 41.5 ± 19.2 | ||||
| CCI score | 0.63 ± 0.88 | −0.028 (0.001) | −0.030 (0.001) | −3.32 (0.067) | −3.23 (0.068) |
| FEV1% | 77.0 ± 18.7 | 0.001 (0.090) | 0.001 (0.087) | 0.208 (0.015) | 0.179 (0.032) |
| Neoadjuvant | 25 (10.9) | ||||
| Clinical stage II‐IV† | 90 (39.1) | ||||
| VATS | 42 (18.7) | −0.044 (0.031) | |||
| Intraoperative features | |||||
| Pathological stage II‐IV† | 71 (30.9) | ||||
| Squamous‐cell carcinoma‡ | 83 (36.1) | ||||
| Large‐cell or undifferentiated carcinoma‡ | 23 (10.0) | ||||
| Lobar or minor resection | 179 (77.8) | ||||
| Adjuvant chemotherapy | 32 (13.9) | 10.9 (0.010) | |||
| Adjuvant radiotherapy | 5 (2.2) | ||||
| Complications | |||||
| Bleeding | 5 (2.2) | −0.071 (0.140) | −20.6 (0.040) | ||
| Air leak | 12 (5.2) | 0.056 (0.085) | |||
| Infection | 17 (7.4) | −0.069 (0.012) | −8.88 (0.111) | ||
| Cardiac | 1 (0.4) | ||||
| Other | 13 (5.7) | −0.063 (0.044) | |||
†
Compared to stage I;
‡
compared to adenocarcinoma. CCI, Charlson comorbidity index; FEV1%, forced expiratory volume in 1 second (FEV1) percentage of the predicted value; HRQoL, health‐related quality of life; SD, standard deviation; SPY, smoke pack‐years (given for smokers); VATS, video‐assisted thoracoscopic surgery; SD, standard deviation.